Pascal Soriot, the firm's chief executive officer, said Cambridge was picked because of its scientific workforce and institutions.
BBC: AstraZeneca axes 700 jobs in Cambridge move
2.
Soriot has smart ideas about which drugs to advance into later testing.
FORBES: Can Pascal Soriot Turn Around AstraZeneca? It May Come Down To One Drug
3.
"Cambridge, which boasts strong links with London-based research institutions, is a world-renowned bioscience hotspot that rivals the likes of San Francisco and Boston, " Mr Soriot said.